Exogenous Ganglioside GM3 Attenuates Atherosclerosis via Multi-Organ Modulation of Lipid Metabolism
Pharmaceutics · 29.04.2026 · 18 (5) · 547
DOI: 10.3390/pharmaceutics18050547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 29.04.2026. Verfasst von Jinhua Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Study, Nanchang University, Nanchang 330031, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Atherosclerosis (AS) remains a leading cause of cardiovascular mortality worldwide and is significantly driven by hyperlipidemia. While ganglioside GM3 is known to regulate cellular lipid metabolism, its systemic pharmacological effects on atherosclerosis remain unclear. This study aims to evaluate the anti-atherosclerotic efficacy of exogenous GM3 and elucidate its underlying systemic mechanisms.
Methods
C57BL/6N ApoE−/− mice fed a high-fat diet were intravenously treated with exogenous GM3 (1 or 4 mg/kg) every three days for 12 weeks. Atherosclerotic progression and lipid profiles were evaluated through histological analyses of the aortic arch and aortic sinus, alongside biochemical and molecular assessments of plasma, hepatic, and intestinal tissues.
Results
GM3 treatment significantly reduced plaque formation in the aortic arch and aortic sinus, along with decreased plasma levels of triglycerides, total cholesterol, and LDL-C. Mechanistically, GM3 suppressed hepatic VLDL secretion by downregulating ApoB100 and MTTP expression. Concurrently, hepatic lipid clearance was enhanced via the upregulation of Ldlr, Scarb1, and Lrp1. GM3 also lowered circulating PCSK9 levels and reduced intestinal cholesterol absorption by decreasing NPC1L1 expression. Although GM3 promoted lipid accumulation in the liver, no evidence of liver dysfunction or systemic toxicity was observed.
Conclusions
Exogenous GM3 acts as a potent multi-target modulator that attenuates atherosclerosis by coordinating hepatic lipoprotein metabolism and restricting intestinal cholesterol uptake. This multi-organ metabolic partitioning strategy highlights the potential of GM3-based therapeutics for managing complex dyslipidemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Advanced Study, Nanchang University, Nanchang 330031, China.
- The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Pharmacy, Nanchang University, Nanchang 330031, China.
- College of Life Sciences, Nanchang University, Nanchang 330031, China.
ORCID-Profile: Hongda Zhuang, Yong Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, J., Zhuang, H., Sheng, Q., Qiu, Z., & Chen, Y. (2026). Exogenous Ganglioside GM3 Attenuates Atherosclerosis via Multi-Organ Modulation of Lipid Metabolism. Pharmaceutics, 18(5), 547. https://doi.org/10.3390/pharmaceutics18050547
Vancouver
Zhou J, Zhuang H, Sheng Q, Qiu Z, Chen Y. Exogenous Ganglioside GM3 Attenuates Atherosclerosis via Multi-Organ Modulation of Lipid Metabolism. Pharmaceutics. 2026;18(5):547. doi:10.3390/pharmaceutics18050547
BibTeX
@article{Zhou2026,
author = {Zhou, Jinhua and Zhuang, Hongda and Sheng, Qinghua and Qiu, Zhitao and Chen, Yong},
title = {Exogenous Ganglioside GM3 Attenuates Atherosclerosis via Multi-Organ Modulation of Lipid Metabolism},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {547},
doi = {10.3390/pharmaceutics18050547}
}
EUVIMED